» Articles » PMID: 24379443

PIASy-mediated Sumoylation of SREBP1c Regulates Hepatic Lipid Metabolism Upon Fasting Signaling

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2014 Jan 1
PMID 24379443
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

SREBP1c is a key transcription factor that regulates de novo lipogenesis during anabolic periods. However, the molecular mechanisms involved in the suppression of SREBP1c under nutritional deprivation are largely unknown. In this study, we demonstrate that the small ubiquitin-related modifier (SUMO) E3 ligase, a protein inhibitor of activated STAT Y (PIASy), sumoylates SREBP1c at Lys98, leading to suppression of the hepatic lipogenic program upon fasting-induced signals. In primary hepatocytes, ablation of PIASy stimulated intracellular lipid accumulation through the induction of SREBP1c and its target genes. Given that protein kinase A (PKA) plays important roles in catabolic responses, activated PKA enhances the sumoylation of SREBP1c and potentiates the interaction between SREBP1c and PIASy. Notably, overexpression of PIASy in obese db/db mice ameliorated hepatic steatosis, while suppression of PIASy in lean (wild-type) mice stimulated hepatic lipogenesis with increased expression of SREBP1c target genes. Furthermore, PKA-mediated SREBP1c phosphorylation augmented SREBP1c sumoylation, subsequently leading to degradation of SREBP1c via ubiquitination. Together, these data suggest that PKA-induced SREBP1c sumoylation by PIASy is a key regulatory mechanism to turn off hepatic lipogenesis during nutritional deprivation.

Citing Articles

Tissue adaptation to metabolic stress: insights from SUMOylation.

Xie H, Liu X, Li S, Wang M, Li Y, Chen T Front Endocrinol (Lausanne). 2024; 15:1434338.

PMID: 39588331 PMC: 11586182. DOI: 10.3389/fendo.2024.1434338.


Abnormal protein SUMOylation in liver disease: novel target for therapy.

Yang Y, Yu F J Mol Med (Berl). 2024; 102(6):719-731.

PMID: 38565749 DOI: 10.1007/s00109-024-02440-w.


Inhibition of visceral adipose tissue-derived pathogenic signals by activation of adenosine AR improves hepatic and cardiac dysfunction of NASH mice.

Huang C, Yeh H, Lin R, Liao T, Shen H, Yang Y Am J Physiol Gastrointest Liver Physiol. 2024; 326(4):G385-G397.

PMID: 38252682 PMC: 11213477. DOI: 10.1152/ajpgi.00104.2023.


Fasting-sensitive SUMO-switch on Prox1 controls hepatic cholesterol metabolism.

Alfaro A, Dittner C, Becker J, Loft A, Mhamane A, Maida A EMBO Rep. 2023; 24(10):e55981.

PMID: 37560809 PMC: 10561358. DOI: 10.15252/embr.202255981.


The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications.

Gu Y, Fang Y, Wu X, Xu T, Hu T, Xu Y Exp Hematol Oncol. 2023; 12(1):58.

PMID: 37415251 PMC: 10324244. DOI: 10.1186/s40164-023-00420-3.


References
1.
Miyauchi Y, Yogosawa S, Honda R, Nishida T, Yasuda H . Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes. J Biol Chem. 2002; 277(51):50131-6. DOI: 10.1074/jbc.M208319200. View

2.
Lee Y, Sohn D, Han D, Lee H, Seong R, Kim J . Chromatin remodeling complex interacts with ADD1/SREBP1c to mediate insulin-dependent regulation of gene expression. Mol Cell Biol. 2006; 27(2):438-52. PMC: 1800793. DOI: 10.1128/MCB.00490-06. View

3.
Shimomura I, Matsuda M, Hammer R, Bashmakov Y, Brown M, Goldstein J . Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell. 2000; 6(1):77-86. View

4.
Mohideen F, Capili A, Bilimoria P, Yamada T, Bonni A, Lima C . A molecular basis for phosphorylation-dependent SUMO conjugation by the E2 UBC9. Nat Struct Mol Biol. 2009; 16(9):945-52. PMC: 2771680. DOI: 10.1038/nsmb.1648. View

5.
Brown M, Goldstein J . A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A. 1999; 96(20):11041-8. PMC: 34238. DOI: 10.1073/pnas.96.20.11041. View